×
About 69,524 results

Lapatinib in Combination With Vinorelbine
https://clinicaltrials.gov/ct2/show/NCT01128543

Dec 11th, 2012 - This is a Multicenter, Open-Label, Phase II Study of lapatinib in Combination with Vinorelbine in women with documented evidence of HER2/neu positive breast cancer which is metastatic or recurrent and with or without prior chemotherapy or anti-HER2/neu targeted therapy in the metastatic and relaps setting. Patients will receive 1250mg lapatinib once a day and vinorelbine 25mg/sqm IV Day 1and Da...

Biological Therapy in Treating Patients With Metastatic Melanoma
https://clinicaltrials.gov/ct2/show/NCT00002786

May 9th, 2010 - OBJECTIVES: Assess the safety and toxicity of cellular adoptive immunotherapy using autologous CD8+ antigen-specific T-cell clones in patients with metastatic melanoma. Estimate the duration of in vivo persistence of adoptively transferred CD8+ antigen-specific cytotoxic T-cell clones in these patients. Evaluate the antitumor effects of CD8+ antigen-specific T-cell clones in these patients. OUT...

Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
https://clinicaltrials.gov/ct2/show/NCT00003426

Jun 20th, 2013 - OBJECTIVES: I. Determine the maximum tolerated dose of gemcitabine in combination with radiation therapy to patients with locally advanced and/or unresectable adenocarcinoma of the pancreas. II. Determine the dose limiting toxic effects of this combination therapy in these patients. III. Evaluate the ability of these patients to tolerate induction and then maintenance therapy with gemcitabine p...

Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT00006465

Jun 10th, 2010 - OBJECTIVES: Determine the maximum tolerated dose and dose-limiting toxicity of irinotecan and capecitabine when given in combination with a fixed dose of oxaliplatin in patients with advanced solid tumors. Determine the pharmacokinetic parameters of this regimen in these patients. Determine the antitumor response of these patients treated with this regimen. OUTLINE: This is a dose-escalation st...

SU5416 in Treating Patients With AIDS-Related Kaposi's Sarcoma
https://clinicaltrials.gov/ct2/show/NCT00005042

Aug 28th, 2014 - OBJECTIVES: I. Determine the antitumor effects of SU5416 in patients with chemotherapy refractory cutaneous AIDS-related Kaposi's sarcoma. II. Determine the safety and tolerability of this regimen in these patients. III. Determine the pharmacokinetics of this regimen in these patients. IV. Determine the safety of this regimen on HIV replication and immune parameters in these patients. V. Determ...

A Phase I Multicenter Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160
https://clinicaltrials.gov/ct2/show/NCT00000956

May 24th, 2012 - Evaluation of previous patients who received doses of 40 or 80 mcg gp160 vaccine indicates that, although serum anti-gp160 antibody responses were detected, the level and duration of those responses were limited. A preliminary observation suggests that weak functional antibody responses may develop following the 18 month booster of 40 or 80 mcg; therefore, a dose of gp160 vaccine having potenti...

Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer
https://clinicaltrials.gov/ct2/show/NCT00033696

Jul 18th, 2016 - OBJECTIVES: Determine the complete and overall response rates in patients with limited stage small cell lung cancer treated with induction chemotherapy comprising paclitaxel, topotecan, and etoposide followed by consolidation chemoradiotherapy. Determine the toxicity of this regimen in these patients. Determine the overall and failure-free survival of patients treated with this regimen. Determi...

Combination Chemotherapy in Treating Patients With Colorectal Cancer
https://clinicaltrials.gov/ct2/show/NCT00039208

Jul 12th, 2012 - OBJECTIVES: Determine the role of peak delivery time on the tolerability of irinotecan when administered with chronomodulated fluorouracil, leucovorin calcium, and oxaliplatin as first- or second-line therapy in patients with locoregional or metastatic colorectal cancer. Determine the antitumor activity of this regimen. OUTLINE: This is a randomized, multicenter study. Patients are stratified a...

Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer
https://clinicaltrials.gov/ct2/show/NCT00019539

Jun 19th, 2013 - OBJECTIVES: I. Determine the effect of monoclonal antibody VEGF on time to progression, angiogenesis, and overall survival in patients with unresectable advanced renal cell cancer. II. Evaluate serum antibody levels and biologically active vascular endothelial growth factor levels in the plasma of patients treated with this regimen. III. Evaluate the toxicity of this regimen in these patients. ...

Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)
https://clinicaltrials.gov/ct2/show/NCT01595438

Sep 5th, 2017 - A Phase III, Randomized, Multicenter, Double-Blind, Double Dummy, Parallel Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam (CAZ-AVI, formerly CAZ104) Versus Doripenem Followed by Appropriate Oral Therapy in the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis, With a Gram Negative Pathogen in Hospitalized Adults

Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT00005791

Dec 18th, 2013 - OBJECTIVES: I. Determine the maximum tolerated dose of weekly irinotecan in combination with weekly fluorouracil and cisplatin in patients with locally advanced or metastatic solid tumors. II. Determine the dose limiting toxicity for this combination regimen in this patient population. III. Establish a recommended phase II dose for this combination regimen in these patients. IV. Evaluate the sa...

Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer
https://clinicaltrials.gov/ct2/show/NCT00004102

Mar 27th, 2011 - OBJECTIVES: I. Evaluate the quantitative and qualitative toxicities of oxaliplatin combined with fluorouracil and leucovorin calcium in patients with advanced adenocarcinoma of the colon or rectum. OUTLINE: Patients receive leucovorin calcium IV over 10-20 minutes followed within 10 minutes by fluorouracil IV bolus on days 1, 8, 15, 29, 36, and 43. Patients receive oxaliplatin IV over 2 hours p...

FR901228 in Treating Patients With Refractory Stomach Cancer or Gastroesophageal Junction Cancer
https://clinicaltrials.gov/ct2/show/NCT00098527

Jul 1st, 2013 - PRIMARY OBJECTIVES: I. Determine the radiographic response rate (complete response and partial response) in patients with refractory adenocarcinoma of the stomach or gastroesophageal junction treated with FR901228 (depsipeptide). SECONDARY OBJECTIVES: I. Determine the median time to progression and progression-free survival of patients treated with this drug. II. Determine the grade 3 and 4 tox...

Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment Naive
https://clinicaltrials.gov/ct2/show/NCT00093093

Jun 21st, 2012 - Compare the efficacy and safety of viramidine 600 mg twice a day (BID) versus ribavirin 1000/1200 mg/day, both drugs administered in combination with pegylated interferon alfa-2a to treatment-naive patients with chronic hepatitis C (CHC)

Electrochemoterapy With Bleomycin for the Treatment of Unresectable Pancreatic Cancer
https://clinicaltrials.gov/ct2/show/NCT03225781

Aug 8th, 2018 - Electrochemotherapy is a type of electroporation that allows the delivery of drugs to the cells through the local creation of pores in the cell membrane. The electric pulses can be applied directly to the neoplastic cells, allowing for the local concentration of a possible chemotherapeutic agent administered through the bloodstream. This technique does not use heat nor other thermal energies an...

Study Evaluating Nivolumab (Anti-PD-1 Antibody) Alone Versus Nivolumab Plus Ipilimumab (Anti-CTLA-4 Antibody) in Patients With Resectable and Potentially Resectable Hepatocellular Carcinoma (HCC) (...
https://clinicaltrials.gov/ct2/show/NCT03222076

Jul 30th, 2018 - Objectives: Primary Objective: 1. To evaluate the safety and tolerability of therapy with nivolumab alone or nivolumab + ipilimumab in resectable HCC in the context of presurgical therapy; to evaluate the safety and tolerability of therapy with nivolumab + ipilimumab in potentially resectable HCC in the context of pre-biopsy therapy. Secondary Objectives: To assess the efficacy of presurgical n...

Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma
https://clinicaltrials.gov/ct2/show/NCT03259425

Sep 12th, 2018 - This is a single-arm, open label, Phase II study evaluating the safety and efficacy of neoadjuvant Nivolumab and HF10 in resectable stage IIIB, IIIC, and IVM1a melanoma.

Safety and Efficacy of Intracameral Zimoxin for Prevention of Endophthalmitis After Cataract Surgery
https://clinicaltrials.gov/ct2/show/NCT03244072

Jun 25th, 2018 - Subjects will receive either intracameral injection of 0.1% moxifloxacin solution or placebo after cataract surgery. They will be followed for one month to determine if there is a statistically significant difference in the incidence of endophthalmitis.

Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer
https://clinicaltrials.gov/ct2/show/NCT00002819

Apr 10th, 2013 - OBJECTIVES: I. Compare progression-free and overall survival of patients with drug-sensitive, low-volume ovarian cancer that is persistent following standard therapy treated with salvage therapy comprising standard-dose paclitaxel and carboplatin vs high-dose carboplatin, mitoxantrone, and cyclophosphamide followed by bone marrow reconstitution. II. Compare the toxic effects of these two salvag...

Combination Chemotherapy With or Without Amifostine in Treating Young Patients With Liver Cancer
https://clinicaltrials.gov/ct2/show/NCT00003994

Jun 13th, 2013 - Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Chemoprotective drugs such as amifostine may protect normal cells from the side effects of chemotherapy. It is not yet known which chemotherapy regimen is most effective for children and young adults with liver cancer. This rand...